PDA 002
Alternative Names: PDA-002; PDAC cells; Placental-derived adherent cells intramuscularLatest Information Update: 28 Nov 2022
At a glance
- Originator Celgene Corporation
- Developer Celgene Corporation; Celularity
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Facioscapulohumeral muscular dystrophy
- Discontinued Diabetic foot ulcer; Diabetic neuropathies; Peripheral arterial disorders
Most Recent Events
- 28 Nov 2022 Preclinical trials in Facioscapulohumeral muscular dystrophy in USA (IM) (Celularity pipeline, November 2022)
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb
- 26 Sep 2018 PDA 002 is still in phase II trials for Diabetic peripheral neuropathy, Peripheral arterial disorders and Diabetic foot ulcer in USA (celularity pipeline, September 2018)